Catalyst hires Michael Kalb as CFO
Plus: Raab to become Amicus chair when Crowley heads to BIO and updates from AC Immune, Gossamer Bio, Chimerix, Versameb, Alzheon, Kling and Avalere
Neurological disease company Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) hired Michael Kalb as EVP and CFO, effective Jan. 1, succeeding Alicia Grande who is retiring at year-end. Kalb was CFO at Impel Pharmaceuticals Inc. (NASDAQ:IMPL), before which he was EVP and CFO of CinCor Pharma Inc. Additionally, Catalyst promoted Steven Miller to EVP, chief operating and scientific officer from COO, and Jeffrey Del Carmen to EVP, chief commercial officer (CCO) from SVP of sales and marketing.
Michael Raab, lead independent director of Amicus Therapeutics Inc. (NASDAQ:FOLD), will become chairman of the rare disease company when Executive Chairman John Crowley departs next spring to become president and CEO of BIO. Crowley will become Amicus chairman emeritus...